The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M01 | Antiinflammatory and antirheumatic products | |
| 3 | M01A | Antiinflammatory and antirheumatic products, non-steroids | |
| 4 | M01AH | Coxibs | |
| 5 | M01AH01 | Celecoxib |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.2 g |
| Active Ingredient | Description | |
|---|---|---|
| Celecoxib |
Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CELEBREX Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| CELEBREX Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| COXLEON Capsule | Health Products Regulatory Authority (ZA) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
